Idelalisib (GS-1101)-Associated Colitis - Molecular and Cellular Mechanisms Research Proposal
Latest Information Update: 20 Jul 2021
Price :
$35 *
At a glance
- Drugs Idelalisib (Primary)
- Indications B-cell lymphoma; Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma
- Focus Pharmacodynamics
- 26 Feb 2019 Status changed from recruiting to discontinued.
- 11 Oct 2017 Planned primary completion date changed from 1 Dec 2028 to 1 Feb 2028.
- 11 Oct 2017 Status changed from not yet recruiting to recruiting.